2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.
Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.
One of the most important findings of the past year was the identification of a form of hereditary prostate cancer, Armstrong says.
These mutations are called homologous repair enzymes, which create a very aggressive form of prostate cancer that effects 10% to 15% of men with metastatic prostate cancer.
Related Content: